Results 101 to 110 of about 11,074 (164)

Minimal residual disease guides postoperative therapy in a patient with ALK-rearranged adenocarcinoma: a case report. [PDF]

Front Oncol
Xian X, Wang K, Wang L, Ke H.
europepmc   +1 more source

Successful Introduction of Lorlatinib After Drug Eruption With Alectinib in ALK-Positive Lung Adenocarcinoma: A Case Report. [PDF]

Respirol Case Rep
Omura S, Sunata K, Tani T, Uchibori K, Shinomiya S, Takahashi S.   +5 more
europepmc   +1 more source

Cost of managing brain metastases in patients with ALK+ advanced NSCLC with first-line tyrosine kinase inhibitors in the UK. [PDF]

Lung Cancer Manag
Le H, Ladino D, Lowry C, Rifi N, Baijal S.   +4 more
europepmc   +1 more source

Clinical Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitors for the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer Based on the 2nd Edition of China's Drug Evaluation and Selection Guideline. [PDF]

Drug Des Devel Ther
Guo Z, Zhang Y, Chen H, Dong X, Lei W, Zhong L, Yang J, Huang H, Chen Z, Liang W.   +9 more
europepmc   +1 more source

Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders

Precise control of pre‑mRNA splicing is vital for transcriptome integrity, and its disruption is an emerging cancer vulnerability. Here, we use indisulam to degrade RBM39 and show that the clinical ALK inhibitor alectinib can be repurposed to inhibit ...
Nijhuis, Anke, yurui, ma
core  

Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rare <i>WDR43::ALK</i> structural deletion. [PDF]

Front Oncol
Epler L, Velasquez G, Mambetsariev I, Arias-Romero J, Fricke J, Chen N, Babikian R, Ngo L, Arvanitis L, Kulkarni AA, Urgun DA, Gruber S, Afkhami M, Salgia R.   +13 more
europepmc   +1 more source

Long-Term Outcomes and Prognostic Factors in Metastatic <i>ALK</i>-Rearranged Non-Small Cell Lung Cancer Treated with ALK Tyrosine Kinase Inhibitors: Real-World Evidence from a High-Volume Thoracic Diseases Center. [PDF]

Cancers (Basel)
Koçanoğlu A, Ünsal O, Kuş F, Gürçay N, Zeynelgil E, Düzköprü Y, Karakaya S.   +6 more
europepmc   +1 more source

Emergence of KRAS mosaicism with multiple variants during treatment with alectinib in ALK-positive metastatic non-small cell lung cancer: A case report. [PDF]

Oncol Lett
Simon A, Treffel G, Pax G, Gauchotte G, Husson M, Hanriot I, Leroux A, Merlin JL, Harlé A, Gilson P.   +9 more
europepmc   +1 more source

Clinical characteristics of ALK-positive NSCLC patients treated with sequential ALK-TKI therapies in a single-centre. [PDF]

Lung Cancer Manag
Fujita K, Imakita T, Fujimoto N, Yoshimura S, Toyama S, Ito T, Oi I, Kanai O, Yamamoto Y, Tanizawa K.   +9 more
europepmc   +1 more source

Refining first-line therapy in ALK-positive non-small cell lung cancer: final overall survival from the ALEX trial and an evolving treatment landscape. [PDF]

J Thorac Dis
Boshkos M, Parma M, Singhi EK.
europepmc   +1 more source